Sunil Singhal
Chairman at Center For Advanced Retinal & Ocular Therapies
Profile
Sunil Singhal is currently holding multiple positions as a Director at Sunlight Fuels Pvt Ltd, an Independent Director at MorphImmune, Inc., a Portfolio Advisor at Forefront Analytics LLC, a Venture Partner at Research Bridge Partners, and Vice Chair of Translational Research at the Center for Advanced Retinal & Ocular Therapies.
He completed his undergraduate degree from Dartmouth College in 1994 and received an MBA from The Wharton School of the University of Pennsylvania in 2018.
Sunil Singhal active positions
| Companies | Position | Start |
|---|---|---|
Sunlight Fuels Pvt Ltd.
 Sunlight Fuels Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Sunlight Fuels Pvt Ltd. is an Indian company that provides business and management consultancy services. The private company is based in New Delhi, India and was founded in 2014. | Director/Board Member | 2014-11-24 |
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Private Equity Investor | 2021-02-28 |
Forefront Analytics LLC
 Forefront Analytics LLC Investment ManagersFinance Forefront Analytics LLC (Forefront) is an independent asset management firm headquartered in West Conshohocken, Pennsylvania. The firm was founded in 2010 by Christopher Geczy and William Thompson. Forefront provides consulting, investment advisory, and investment management services to ultra-high-net worth individuals and families, investment limited partnerships, trusts, corporations, and other business entities. | Consultant / Advisor | 2020-02-29 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Director/Board Member | 2020-09-30 |
| Center For Advanced Retinal & Ocular Therapies | Chairman | 2017-12-31 |
Training of Sunil Singhal
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Dartmouth College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Sunlight Fuels Pvt Ltd.
Sunlight Fuels Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Sunlight Fuels Pvt Ltd. is an Indian company that provides business and management consultancy services. The private company is based in New Delhi, India and was founded in 2014. | Commercial Services |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |
Forefront Analytics LLC
Forefront Analytics LLC Investment ManagersFinance Forefront Analytics LLC (Forefront) is an independent asset management firm headquartered in West Conshohocken, Pennsylvania. The firm was founded in 2010 by Christopher Geczy and William Thompson. Forefront provides consulting, investment advisory, and investment management services to ultra-high-net worth individuals and families, investment limited partnerships, trusts, corporations, and other business entities. | Finance |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
| Center For Advanced Retinal & Ocular Therapies |
- Stock Market
- Insiders
- Sunil Singhal
